Evidence map›Paper›PMID 28259709›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2017

Consensus classification of posterior cortical atrophy.

Sebastian J Crutch, Jonathan M Schott, Gil D Rabinovici, Melissa Murray, Julie S Snowden, Wiesje M van der Flier, Bradford C Dickerson, Rik Vandenberghe, Samrah Ahmed, Thomas H Bak and 30 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 342 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
342citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

342 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. 2 mA is NOT 2 mA: Electric field variability in high-definition tDCS and its implications for precision neuromodulation in aging.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2026
    Article
  13. Posterior cortical atrophy: a diagnostic challenge in a patient with delayed recognition of progressive visuospatial dysfunction.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

282 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Sebastian J CrutchDementia Research Centre, UCL Institute of Neurology, London, UK. Electronic address: s.crutch@ucl.ac.uk.
Jonathan M SchottDementia Research Centre, UCL Institute of Neurology, London, UK.
Gil D RabinoviciDepartment of Neurology, Memory & Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Melissa MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Julie S SnowdenCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust, Salford, UK; Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.
Wiesje M van der FlierDepartment of Neurology, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands; Alzheimer Center, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Samrah AhmedNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Thomas H BakHuman Cognitive Neuroscience, School of Philosophy, Psychology and Language Sciences, University of Edinburgh, Edinburgh, UK.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Christopher ButlerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Stefano F CappaCenter for Cognitive Neuroscience, Vita-Salute San Raffaele University, Milan, Italy.
Mathieu CeccaldiINSERM U 1106, Institut des Neurosciences des Systèmes, Aix Marseille Université, Marseilles, France.
Leonardo Cruz de SouzaDepartamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Bruno DuboisInstitute for Memory and Alzheimer's Disease, UMR-S975, Salpêtrière Hospital, Pierre & Marie Curie University, Paris, France.
Olivier FelicianAix-Marseille Université, INSERM, Institut de Neurosciences des Systèmes, Marseille, France; AP-HM Hôpitaux de la Timone, Service de Neurologie et Neuropsychologie, Marseille, France.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, San Diego, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Patrick R HofFishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, USA; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Pierre Krolak-SalmonClinical and Research Memory Center of Lyon, Hospices Civils de Lyon, INSERM U1028, CNRS UMR5292, University of Lyon, Lyon, France.
Manja LehmannDementia Research Centre, UCL Institute of Neurology, London, UK; Department of Neurology, Memory & Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Eloi MagninDepartment of Neurology, Regional Memory Centre (CMRR), CHU Besançon, Besançon, France.
Mario F MendezDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Peter J NestorCognitive Neurology and Neurodegeneration Group, German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Victoria S PelakDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA; Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA.
Yolande PijnenburgDepartment of Neurology, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands; Alzheimer Center, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Silvia PrimativoDementia Research Centre, UCL Institute of Neurology, London, UK.
Martin N RossorDementia Research Centre, UCL Institute of Neurology, London, UK.
Natalie S RyanDementia Research Centre, UCL Institute of Neurology, London, UK.
Philip ScheltensDepartment of Neurology, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands; Alzheimer Center, VU University Medical Centre, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Timothy J ShakespeareDementia Research Centre, UCL Institute of Neurology, London, UK.
Aida Suárez GonzálezDementia Research Centre, UCL Institute of Neurology, London, UK; Memory Disorders Unit, Neurology Department, University Hospital Virgen del Rocio, Seville, Spain.
David F Tang-WaiDivision of Neurology, University Health Network Memory Clinic, University of Toronto, Toronto, Ontario, Canada.
Keir X X YongDementia Research Centre, UCL Institute of Neurology, London, UK.
Maria CarrilloMedical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
Nick C FoxDementia Research Centre, UCL Institute of Neurology, London, UK.
Alzheimer's Association ISTAART Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHIMMING, CORBETT · 1985 to 2019
$37.9M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Effects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Medical Research Council MR/K010395/1NIA NIH HHS P50 AG005131NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG048234NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

introductionA classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.

methodsConsensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.

resultsA three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. DISCUSSION: There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.

Indexed as

BrainBrain DiseasesHumansAlzheimer's diseaseBiomarkerClinico-radiological syndromePathophysiologyPosterior cortical atrophy

Identifiers

PMID28259709
PMCPMC5788455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.